# Relates to mandating insurance coverage for medical devices to treat withdrawal symptoms

**Bill ID:** A960
**Session:** 2023
**Sponsor:** Linda Rosenthal
**Status:** In Assembly Committee
**PDF:** [A960 PDF](https://legislation.nysenate.gov/pdf/bills/2023/A960)

## Summary

Relates to mandating insurance coverage for medical devices and products to treat withdrawal symptoms which are approved by the food and drug administration.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  960
 
  2023-2024 Regular Sessions
 
  I N  A S S E M B L Y
 
  January 11, 2023
  ___________
 
 Introduced  by  M.  of  A. L. ROSENTHAL -- read once and referred to the
  Committee on Insurance
 
 AN ACT to amend the insurance law, in relation  to  mandating  insurance
  coverage for medical devices to treat withdrawal symptoms
 
  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section 1. Subparagraph (A) of  paragraph  30  of  subsection  (i)  of
 section  3216 of the insurance law, as amended by section 5 of subpart A
 of part BB of chapter 57 of the laws of 2019,  is  amended  to  read  as
 follows:
  (A)  Every  policy  that  provides  hospital, major medical or similar
 comprehensive coverage shall provide inpatient coverage for the  diagno-
 sis  and  treatment  of substance use disorder, including detoxification
 and rehabilitation services, INCLUDING THE USE OF  MEDICATIONS,  MEDICAL
 DEVICES AND PRODUCTS APPROVED AND/OR CLEARED BY THE FOOD AND DRUG ADMIN-
 ISTRATION  FOR  THE  TREATMENT  OF  WITHDRAWAL  SYMPTOMS. Such inpatient
 coverage shall  include  unlimited  medically  necessary  treatment  for
 substance  use  disorder  treatment  services  provided  in  residential
 settings. Further, such inpatient coverage  shall  not  apply  financial
 requirements  or  treatment  limitations,  including  utilization review
 requirements, to inpatient substance use disorder benefits that are more
 restrictive than the predominant financial  requirements  and  treatment
 limitations  applied  to substantially all medical and surgical benefits
 covered by the policy.
  § 2. Paragraph 30 of subsection (i) of section 3216 of  the  insurance
 law, as amended by section 7 of subpart B of part J of chapter 57 of the
 laws of 2019, is renumbered paragraph 30-a.
  §  3. Paragraph 7-a of subsection (l) of section 3221 of the insurance
 law, as added by chapter 748 of the laws of 2019, is amended to read  as
 follows:
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD01272-01-3
 A. 960  2
 
  (7-a) (A) Every policy that provides medical, major medical or similar
 comprehensive-type large group coverage shall provide immediate coverage
 for  all  buprenorphine  products,  methadone  or long acting injectable
 naltrexone, INCLUDING MEDICAL DEVICES OR PRODUCTS FOR THE  TREATMENT  OF
 WITHDRAWAL  SYMPTOMS, without prior authorization for the detoxification
 or maintenance treatment of a substance use disorder.
  (B) Coverage provided under this paragraph may be  subject  to  copay-
 ments,  coinsurance,  and  annual  deductibles  that are consistent with
 those imposed on other benefits within the policy.
  § 4. Subsection (l-1) of section 4303 of the insurance law,  as  added
 by chapter 748 of the laws of 2019, is amended to read as follows:
  (l-1)  (A)  Every  contract  that  provides medical, major medical, or
 similar comprehensive-type large group coverage shall provide  immediate
 coverage  for  all  buprenorphine  products,  methadone  or  long acting
 injectable naltrexone, INCLUDING ANY MEDICAL DEVICES OR PRODUCTS FOR THE
 TREATMENT OF WITHDRAWAL SYMPTOMS, without prior  authorization  for  the
 detoxification or maintenance treatment of a substance use disorder.
  (B)  Coverage  provided  under this paragraph may be subject to copay-
 ments, coinsurance, and annual  deductibles  that  are  consistent  with
 those imposed on other benefits within the policy.
  §  5.  Subparagraph  (A)  of paragraph 31 of subsection (i) of section
 3216 of the insurance law, as amended by section 6 of subpart A of  part
 BB of chapter 57 of the laws of 2019, is amended to read as follows:
  (A)  Every  policy  that  provides  medical,  major medical or similar
 comprehensive-type coverage shall provide outpatient  coverage  for  the
 diagnosis and treatment of substance use disorder, including detoxifica-
 tion  and  rehabilitation  services,  INCLUDING  THE USE OF MEDICATIONS,
 MEDICAL DEVICES AND PRODUCTS APPROVED AND/OR CLEARED  BY  THE  FOOD  AND
 DRUG  ADMINISTRATION  FOR  THE  TREATMENT OF WITHDRAWAL SYMPTOMS.  Such
 coverage shall not apply financial requirements or treatment limitations
 to outpatient substance use disorder benefits that are more  restrictive
 than  the  predominant  financial requirements and treatment limitations
 applied to substantially all medical and surgical  benefits  covered  by
 the policy.
  §  6.  This act shall take effect immediately and shall apply to poli-
 cies and contracts issued, renewed, modified, altered or amended on  and
 after such date.